September 9, 2026 – As part of the White House Anti-Fraud Task Force’s ongoing efforts to crush fraud in the healthcare system and protect taxpayer dollars, the Centers for Medicare & Medicaid Services (CMS) has identified and is barring 11 medical supply companies with more than $3.4 billion in suspected fraudulent billing practices in 2025 and 2026 from receiving future Medicare Advantage (MA) Part C and Part D payments. These 11 durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) suppliers, (1) had submitted no claims prior to 2025; (2) used improper billing practices for their claims; (3) had billed for medical equipment to beneficiaries already deceased; and (4) supplied equipment to beneficiaries who never requested or received it. Four of the suppliers had already been revoked from Original Medicare and began billing Medicare Advantage plans instead.
Working in coordination with the U.S. Department of Health and Human Services Office of Inspector General (HHS-OIG), CMS is ensuring the suppliers will no longer receive payments for healthcare items, services, or drugs, furnished, ordered or prescribed to Medicare beneficiaries and paid for by MA and Part D sponsors. The placement of the 11 suppliers on the CMS Preclusion List was made after it was determined that their conduct was detrimental to the best interests of the Medicare program.
CMS will continue working with HHS-OIG and other program integrity partners to identify suspicious billing, protect beneficiaries, safeguard the Medicare Trust Fund, and ensure Medicare dollars support legitimate healthcare, not fraud.